Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Claudio, P. P.
Right arrow Articles by Giordano, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Claudio, P. P.
Right arrow Articles by Giordano, A.
[Cancer Research 60, 8-12, January 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Mutations in the Retinoblastoma-related Gene RB2/p130 in Primary Nasopharyngeal Carcinoma1

Pier Paolo Claudio, Candace M. Howard, Yan Fu, Caterina Cinti, Luigi Califano, Pietro Micheli, Edward W. Mercer, Mario Caputi and Antonio Giordano2

Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, and Sbarro Institute for Cancer Research and Molecular Medicine, Philadelphia, Pennsylvania 19107 [P. P. C., C. M. H., Y. F., A. G.]; Universitá degli Studi di Napoli "Federico II," Dipartimento di Scienze Odontostomatologiche e Maxillo Facciali, Napoli 80131, Italy [P. P. C., L. C.]; Istituto di Citomorfologia Normale e Patologica, Consiglio Nazionale delle Ricerche, 40136 Bologna, Italy [C. C.]; Servizio di Anatomia ed Istologia Patologica e Citologia Diagnostica, Azienda Ospedaliera "Cotugno," Napoli, Italy [P. M.]; Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [E. W. M.]; and Istituto di Malattie dell’Apparato Respiratorio, II Universitá degli Studi di Napoli, Istituto di Ricerca Cardio-Pneumologica A. O. "Monaldi," Napoli, Italy [M. C.]

Nasopharyngeal carcinoma (NPC) is an endemic cancer in southern China and northern Africa, and its pathogenesis is not yet well defined at the molecular level. Although the involvement of p53 and of the retinoblastoma gene (RB/p105) in NPC has been well studied, there is paucity of mutational data regarding the retinoblastoma-related gene RB2/p130 in primary tumors and particularly in NPC. We have shown previously that RB2/p130 could be rearranged in a nasopharyngeal cell line. In the present study, we screened by single-strand conformation polymorphism and sequence analysis the retinoblastoma-related gene RB2/p130 for mutations within exons 19–22. Mutations in the RB2/p130 gene were detected in 3 of 10 primary human NPCs from Northern Africa (30%). These findings, along with previous data showing that genetic replacement of RB2/p130 restores a normal growth pathway in the nasopharyngeal cell line Hone-1, strengthen the hypothesis that genetic changes of RB2/p130 may be involved in the development and/or progression of nasopharyngeal cancer and suggest that RB2/p130 could be considered a tumor suppressor gene and may be a candidate for novel gene therapeutic approaches for NPC.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
H. Yang, R. Zhao, and M.-H. Lee
14-3-3{sigma}, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma.
Mol. Cancer Ther., February 1, 2006; 5(2): 253 - 260.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Russo, A. Zamparelli, C. M. Howard, C. Minimo, C. Bellan, G. Carillo, L. Califano, L. Leoncini, A. Giordano, and P. P. Claudio
Expression of Cell Cycle-Regulated Proteins pRB2/p130, p107, E2F4, p27, and pCNA in Salivary Gland Tumors: Prognostic and Diagnostic Implications
Clin. Cancer Res., May 1, 2005; 11(9): 3265 - 3273.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Huynh
Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma
Carcinogenesis, August 1, 2004; 25(8): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. D'Andrilli, V. Masciullo, L. Bagella, T. Tonini, C. Minimo, G. F. Zannoni, R. L. Giuntoli II, J. A. Carlson Jr., D. R. Soprano, K. J. Soprano, et al.
Frequent Loss of pRb2/p130 in Human Ovarian Carcinoma
Clin. Cancer Res., May 1, 2004; 10(9): 3098 - 3103.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Caputi, A. M. Groeger, V. Esposito, A. De Luca, V. Masciullo, A. Mancini, F. Baldi, E. Wolner, and A. Giordano
Loss of pRb2/p130 Expression Is Associated with Unfavorable Clinical Outcome in Lung Cancer
Clin. Cancer Res., December 1, 2002; 8(12): 3850 - 3856.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pathol.Home page
A J Alvi, R Hogg, J S Rader, M J Kuo, E R Maher, and F Latif
Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer
Mol. Pathol., June 1, 2002; 55(3): 153 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. P. Claudio, A. Zamparelli, F. U. Garcia, L. Claudio, G. Ammirati, A. Farina, A. Bovicelli, G. Russo, G. G. Giordano, D. E. McGinnis, et al.
Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27kip1, p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland Adenocarcinoma
Clin. Cancer Res., June 1, 2002; 8(6): 1808 - 1815.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Chestukhin, L. Litovchick, K. Rudich, and J. A. DeCaprio
Nucleocytoplasmic Shuttling of p130/RBL2: Novel Regulatory Mechanism
Mol. Cell. Biol., January 15, 2002; 22(2): 453 - 468.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. G. Gray, X. Guo, D. Kedra, B. T. Teh, X. Guo, and H.-Q. Min
Correspondence re: P. P. Claudio et al., Mutations in the Retinoblastoma-related Gene RB2/p130 in Primary Nasopharyngeal Carcinoma. Cancer Res., 60: 8-12, 2000.
Cancer Res., August 1, 2001; 61(15): 5950 - 5951.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
P. P. Claudio, C. Cinti, M. G. Paggi, and A. Giordano
Reply
Cancer Res., August 1, 2001; 61(15): 5952 - 5953.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. G. Paggi and A. Giordano
Who Is the Boss in the Retinoblastoma Family? The Point of View of Rb2/p130, the Little Brother
Cancer Res., June 1, 2001; 61(12): 4651 - 4654.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-W. Lo, P. M. L. Teo, A. B.-Y. Hui, K.-F. To, Y.-S. Tsang, S. Y.-Y. Chan, K.-F. Mak, J. C. K. Lee, and D. P. Huang
High Resolution Allelotype of Microdissected Primary Nasopharyngeal Carcinoma
Cancer Res., July 1, 2000; 60(13): 3348 - 3353.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
C. M. Howard, P. P. Claudio, Antonio De Luca, P. Stiegler, F. P. Jori, N. M. Safdar, M. Caputi, K. Khalili, and A. Giordano
Inducible pRb2/p130 Expression and Growth-suppressive Mechanisms: Evidence of a pRb2/p130, p27Kip1, and Cyclin E Negative Feedback Regulatory Loop
Cancer Res., May 1, 2000; 60(10): 2737 - 2744.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. P. Claudio, M. Caputi, and A. Giordano
The RB2/p130 Gene: The Latest Weapon in the War against Lung Cancer?
Clin. Cancer Res., March 1, 2000; 6(3): 754 - 764.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.